|
2023 Conference Publication Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trialKhattak, Adnan, Weber, Jeffrey S., Meniawy, Tarek, Taylor, Matthew H., Ansstas, George, Kim, Kevin B., McKean, Meredith, Long, Georgina V., Sullivan, Ryan J., Faries, Mark B., Tran, Thuy, Cowey, Charles Lance, Medina, Theresa Michelle, Segar, Jennifer Margaret, Atkinson, Victoria, Gibney, Geoffrey Thomas, Luke, Jason J., Buchbinder, Elizabeth Iannotti, Meehan, Robert S., Carlino, Matteo S. and on behalf of Moderna Author's Group (2023). Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. 2023 ASCO Annual Meeting, Chicago, IL United States, 2-6 June 2023. Philadelphia, PA United States: Lippincott Williams & Wilkins. doi: 10.1200/JCO.2023.41.17_suppl.LBA9503 |
|
2022 Conference Publication Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinomaAoude, L.G., Bonazzi, V.F., Brosda, S., Wong, B., Moradi, H., Lonie, J., Bradford, J., Bloxham, C., Atkinson, V.G., Law, P., Lampe, G., Smithers, M., Waddell, N., Vegh, V., Miles, K. and Barbour, A.P. (2022). Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinoma. ESMO Congress 2022, Singapore, 9 - 13 September 2022. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2022.07.1357 |
|
2022 Conference Publication Outcomes of neoadjuvant and definitive CROSS (carboplatin and paclitaxel chemoradiotherapy) in oesophageal cancerIqbal, Samreen, Atkinson, Victoria, Arneil, Melissa, Andelkovic, Vladimir and Roberts, Kate Elizabeth (2022). Outcomes of neoadjuvant and definitive CROSS (carboplatin and paclitaxel chemoradiotherapy) in oesophageal cancer. 2022 ASCO Annual Meeting, Chicago, IL United States, 3-7 June 2022. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2022.40.16_suppl.e16033 |
|
2019 Conference Publication Patterns of response for combination of PV-10 oncolytic immunotherapy and checkpoint inhibitionAgarwala, Sanjiv S., Ross, Merrick I., Zager, Jonathan, Shirai, Keisuki, Essner, Richard, Smithers, Bernard M., Atkinson, Victoria, Sarson, David and Wachter, Eric A. (2019). Patterns of response for combination of PV-10 oncolytic immunotherapy and checkpoint inhibition. LONDON: BMC. |
|
2019 Conference Publication Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanomaTie, Emilia Nan, Lai-Kwon, Julia Elizabeth, Na, Lumine, Rtshiladze, Michael Alexander, Bozzi, James, Read, Tavis, Atkinson, Victoria, Au-Yeung, George, Long, Georgina V., McArthur, Grant A., Sandhu, Shahneen Kaur, Saw, Robyn, Walpole, Euan Thomas, Menzies, Alexander M., Smithers, B. Mark and Gyorki, David E. (2019). Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanoma. Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL United States, 31 May - 4 June 2019. Alexandria, VA United States: American Society of Clinical Oncology. |
|
2018 Conference Publication Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238)Weber, Jeffrey S., Mandala, Mario, Del Vecchio, Michele, Gogas, Helen, Arance, Ana M., Cowey, C. Lance, Dalle, Stephane, Schenker, Michael, Chiarion-Sileni, Vanna, Marquez-Rodas, Ivan, Grob, Jean-Jacques, Butler, Marcus, Middleton, Mark R., Maio, Michele, Atkinson, Victoria, Dummer, Reinhard, de Pril, Veerle, Qureshi, Anila, Larkin, James and Ascierto, Paolo A. (2018). Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238). National-Cancer-Research-Institute (NCRI) Cancer Conference, Glasgow Scotland, Nov 04-06, 2018. LONDON: NATURE PUBLISHING GROUP. |
|
2018 Conference Publication Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D plus T) or placebo (Pbo) in the COMBI-AD trialAtkinson, V. G., Hauschild, A., Santinami, M., Mandala, M., Sileni, V. Chiarion, Larkin, J., Nyakas, M. S., Dutriaux, C., Haydon, A., Mortier, L., Robert, C., Schachter, J., Schadendorf, D., Feng, X., de Jong, E., Mookerjee, B., Kefford, R., Dummer, R., Kirkwood, J. M. and Long, G. V. (2018). Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D plus T) or placebo (Pbo) in the COMBI-AD trial. 43rd ESMO Congress (ESMO), Munich Germany, Oct 19-23, 2018. OXFORD: OXFORD UNIV PRESS. |
|
2018 Conference Publication Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanomaLong, G. V., Hauschild, A., Santinami, M., Atkinson, V. G., Mandala, M., Chiarion-Sileni, V., Larkin, J., Robert, C., Schadendorf, D., Dasgupta, K., Shilkrut, M., Garrett, J., Brase, J. C., Kefford, R., Kirkwood, J. M. and Dummer, R. (2018). Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma. 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19-23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy424.053 |
|
2018 Conference Publication Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trialDummer, R., Schadendorf, D., Hauschild, A., Santinami, M., Atkinson, V. G., Mandala, M., Sileni, V. Chiarion, Larkin, J., Nyakas, M. S., Dutriaux, C., Haydon, A., Mortier, L., Robert, C., Schachter, J., Feng, X., de Jong, E., Mookerjee, B., Kefford, R., Kirkwood, J. M. and Long, G. V. (2018). Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. 43rd ESMO Congress (ESMO), Munich Germany, Oct 19-23, 2018. OXFORD: OXFORD UNIV PRESS. |
|
2018 Conference Publication Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib plus trametinib (D plus T) in patients (pts) with resected BRAF V600-mutant stage III melanomaLong, G. V., Hauschild, A., Santinami, M., Atkinson, V. G., Mandala, M., Chiarion-Sileni, V., Larkin, J., Robert, C., Schadendorf, D., Dasgupta, K., Shilkrut, M., Garrett, J., Brase, J. C., Kefford, R., Kirkwood, J. M. and Dummer, R. (2018). Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib plus trametinib (D plus T) in patients (pts) with resected BRAF V600-mutant stage III melanoma. 43rd ESMO Congress (ESMO), Munich Germany, Oct 19-23, 2018. OXFORD: OXFORD UNIV PRESS. |
|
2018 Conference Publication ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanomaAscierto, P. A., Arenberger, P., Atkinson, V. G., Hansson, J., Kapiteijn, E., Loquai, C., Negrier, S., Shaw, H. M., Tarhini, A., Walker, J., Geib, J., Rahimian, S., Swann, S. and Diab, A. (2018). ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma. 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19–23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy289.062 |
|
2018 Conference Publication ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanomaAscierto, P. A., Arenberger, P., Atkinson, V. G., Hansson, J., Kapiteijn, E., Loquai, C., Negrier, S., Shaw, H. M., Tarhini, A., Walker, J., Geib, J., Rahimian, S., Swann, S. and Diab, A. (2018). ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma. 43rd ESMO Congress (ESMO), Munich Germany, Oct 19-23, 2018. OXFORD: OXFORD UNIV PRESS. |
|
2018 Conference Publication CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanomaLipson, E. J., Long, G. V., Tawbi, H., Schadendorf, D., Atkinson, V. G., Maurer, M., Simonsen, K. L., Harbison, C. and Hodi, F. S. (2018). CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma. 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19–23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy289.058 |
|
2018 Conference Publication CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanomaLipson, E. J., Long, G. V., Tawbi, H., Schadendorf, D., Atkinson, V. G., Maurer, M., Simonsen, K. L., Harbison, C. and Hodi, F. S. (2018). CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma. 43rd ESMO Congress (ESMO), Munich Germany, Oct 19-23, 2018. OXFORD: OXFORD UNIV PRESS. |
|
2018 Conference Publication Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trialAtkinson, V. G., Hauschild, A., Santinami, M., Mandala, M., Chiarion Sileni, V., Larkin, J., Nyakas, M. S., Dutriaux, C., Haydon, A., Mortier, L., Robert, C., Schachter, J., Schadendorf, D., Feng, X., de Jong, E., Mookerjee, B., Kefford, R., Dummer, R., Kirkwood, J. M. and Long, G. V. (2018). Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial. 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19–23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy289.007 |
|
2018 Conference Publication Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trialDummer, R., Schadendorf, D., Hauschild, A., Santinami, M., Atkinson, V. G., Mandala, M., Chiarion Sileni, V., Larkin, J., Nyakas, M. S., Dutriaux, C., Haydon, A., Mortier, L., Robert, C., Schachter, J., Feng, X., de Jong, E., Mookerjee, B., Kefford, R., Kirkwood, J. M. and Long, G. V. (2018). Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. 43rd ESMO Congress (ESMO 2018), Munich, Germany, 19–23 October 2018. Amsterdam, Netherlands: Elsevier. doi: 10.1093/annonc/mdy289.006 |
|
2017 Conference Publication COMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K-mutant melanomaHauschild, A., Santinami, M., Long, G. V., Atkinson, V., Mandala, M., Sileni, V. Chiarion, Nyakas, M. S., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Schachter, J., Ji, R., Zhang, P., Mookerjee, B., Legos, J., Kefford, R., Dummer, R. and Kirkwood, J. (2017). COMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K-mutant melanoma. 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid Spain, Sep 08-12, 2017. OXFORD: OXFORD UNIV PRESS. |
|
2017 Conference Publication Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)Weber, J., Mandala, M., Del Vecchio, M., Gogas, H., Arance, A. M., Cowey, L. C., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J-J., Butler, M., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., de Pril, V., Qureshi, A., Larkin, J. and Ascierto, P. A. (2017). Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238). 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid Spain, Sep 08-12, 2017. OXFORD: OXFORD UNIV PRESS. |
|
2017 Conference Publication A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600-mutant melanoma (COMBI-i)Gasal, E., Arance Fernandez, A. M., Ascierto, P. A., Atkinson, V., Dummer, R., Flaherty, K. T., Grob, J-J., Hansson, J., Hassel, J., Larkin, J., Lebbe, C., Long, G. V., Lorigan, P., Miller, W., Nathan, P., Ribas, A., Robert, C., Schadendorf, D., Tawbi, H. and Upalawanna, A. (2017). A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600-mutant melanoma (COMBI-i). 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid Spain, Sep 08-12, 2017. OXFORD: OXFORD UNIV PRESS. |
|
2017 Conference Publication Survival of Uveal Melanoma Patients Treated With Combination and Single-Agent ImmunotherapyCaldwell, Reece, Mason, Robert and Atkinson, Victoria (2017). Survival of Uveal Melanoma Patients Treated With Combination and Single-Agent Immunotherapy. COSA's 44th Annual Scientific Meeting, Immunotherapy: Molecules and Mountains, Sydney, NSW Australia, 13–15 November 2017. Hoboken, NJ United States: Wiley. |
